Market Size of Lacrimal Duct Stent Tube Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 5.20 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Lacrimal Duct Stent Tube Market Analysis
The lacrimal duct stent tube market is anticipated to record a CAGR of 5.2% over the forecast period.
The COVID-19 pandemic presented significant hurdles for the healthcare sector. Since the majority of surgical procedures were considered to be non-urgent, all outpatient consultations were delayed or restricted during the COVID-19 pandemic to lower the danger of viral transmission. Thus, the lacrimal duct stent market was adversely impacted during the pandemic. However, it is expected to gain traction in the post-pandemic era due to the resumption of surgical procedures.
Certain factors that are driving the market include the increasing patient pool for nasolacrimal duct obstruction and rising demand for treatments with minimal invasions and better success rates. Nasolacrimal duct obstruction (NLDO) or dacryostenosis is the most common disorder of the lacrimal system. According to the August 2022 updated report, published by the NCBI, congenital nasolacrimal duct obstruction may occur in 3-6% of newborns, while it occurs bilaterally in 20% of newborns. There is a high rate of spontaneous resolution of congenital nasolacrimal duct obstruction, with approximately 70% of affected children being free of the symptoms by 3 months of age, and over 90% recovering by their first birthday. However, infants at increased risk for this condition include those with trisomy 21, ectrodactyly-ectodermal dysplasia-cleft lip/palate (EEC) syndrome, branchiooculofacial syndrome, CHARGE (coloboma, heart anomaly, choanal atresia, and retardation, genital, and ear anomalies) syndrome, and Goldenhar syndrome. Hence, the rising prevalence of such health conditions is expected to drive the market over the forecast period.
New studies on lacrimal stent tubes help expand the applications for various conditions, which is expected to boost the market's growth over the forecast period. For instance, as per the study published by the European Journal of Ophthalmology in December 2021, lacrijet monocanalicular stent intubation has a high rate of success, shortens the surgical time, and has a low rate of complications in children with congenital nasolacrimal duct obstruction. Hence, the new studies on lacrimal stent tubes expand the indications and provide the safety and efficacy of the stents, which may drive the market over the forecast period.
However, complications associated with stent tubes are likely to hinder the growth of the market over the forecast period.
Lacrimal Duct Stent Tube Industry Segmentation
As per the scope of the report, a lacrimal stent is a hollow silicone tubing with a non-traumatic tip. The tubing is securely attached to malleable stainless steel probes that are used to guide the silicone tubing through the lacrimal drainage apparatus. Lacrimal stents are used to reduce the risk of recurrent stenosis of the nasolacrimal duct.
The lacrimal duct stent tube market is segmented by product type (monocanalicular lacrimal duct stent tube and bicanalicular lacrimal duct stent tube), end user (hospitals, ophthalmic clinics, and other end users), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Product Type | |
| Monocanalicular Lacrimal Duct Stent Tube | |
| Bicanalicular Lacrimal Duct Stent Tube |
| By End User | |
| Hospitals | |
| Ophthalmic Clinics | |
| Other End Users |
| By Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Lacrimal Duct Stent Tube Market Size Summary
The lacrimal duct stent tube market is poised for growth, driven by an increasing patient pool suffering from nasolacrimal duct obstruction and a rising demand for minimally invasive treatments with higher success rates. The market experienced setbacks during the COVID-19 pandemic due to the postponement of non-urgent surgical procedures, but it is expected to recover as surgical activities resume. The prevalence of conditions such as congenital nasolacrimal duct obstruction, particularly in newborns and those with specific syndromes, is anticipated to propel market expansion. Advances in research and new studies are expanding the applications and improving the safety and efficacy of lacrimal stent tubes, further contributing to market growth. However, complications associated with stent tubes may pose challenges to market progression.
North America is projected to witness significant growth in the lacrimal duct stent tube market, with the United States leading due to favorable regulatory conditions and increased awareness of treatment options. The high incidence of nasolacrimal duct obstruction in the region, coupled with ongoing research, is driving demand for these stents. The market is characterized by a few major players, including Aurolab, Bess Medizintechnik GmbH, and ZEISS (FCI Ophthalmics), who hold substantial market shares. Recent product launches, such as DEXTENZA and LacriJet, highlight ongoing innovation in the field. Comparative studies on the efficacy of different stent types are also influencing market dynamics, as they provide insights into the best practices for managing lacrimal disorders.
Lacrimal Duct Stent Tube Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increasing Patient Pool for Nasolacrimal Duct Obstruction
-
1.2.2 Rising Demand for Treatments with Minimal Invasions and Better Success Rates
-
-
1.3 Market Restraints
-
1.3.1 Complications Associated with Stent Tubes
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD million)
-
2.1 By Product Type
-
2.1.1 Monocanalicular Lacrimal Duct Stent Tube
-
2.1.2 Bicanalicular Lacrimal Duct Stent Tube
-
-
2.2 By End User
-
2.2.1 Hospitals
-
2.2.2 Ophthalmic Clinics
-
2.2.3 Other End Users
-
-
2.3 By Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Lacrimal Duct Stent Tube Market Size FAQs
What is the current Lacrimal Duct Stent Tube Market size?
The Lacrimal Duct Stent Tube Market is projected to register a CAGR of 5.20% during the forecast period (2024-2029)
Who are the key players in Lacrimal Duct Stent Tube Market?
ZEISS (FCI Ophthalmics), Aurolab, bess medizintechnik gmbh, Kaneka Medical America LLC and Gunther Weiss Scientific Glassblowing Co., Inc. are the major companies operating in the Lacrimal Duct Stent Tube Market.
